Last reviewed · How we verify
IPTi
IPTi (Intermittent Preventive Treatment in infants) is a malaria prevention strategy that administers antimalarial drugs at scheduled intervals to infants to prevent malaria infection and disease.
IPTi (Intermittent Preventive Treatment in infants) is a malaria prevention strategy that administers antimalarial drugs at scheduled intervals to infants to prevent malaria infection and disease. Used for Malaria prevention in infants in endemic regions, Reduction of malaria morbidity and mortality in infants aged 2-11 months.
At a glance
| Generic name | IPTi |
|---|---|
| Also known as | SP brand being used is Fansidar |
| Sponsor | Swiss Tropical & Public Health Institute |
| Drug class | Antimalarial preventive strategy |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Parasitology |
| Phase | Phase 3 |
Mechanism of action
IPTi involves giving therapeutic doses of antimalarial medications (typically sulfadoxine-pyrimethamine or other agents) to infants at defined intervals during their first year of life, regardless of malaria infection status. This approach maintains therapeutic drug levels in the blood during high-risk periods, preventing parasitemia and clinical malaria episodes. The strategy is designed to reduce the burden of malaria in infants in endemic areas while allowing some natural immunity development.
Approved indications
- Malaria prevention in infants in endemic regions
- Reduction of malaria morbidity and mortality in infants aged 2-11 months
Common side effects
- Adverse events dependent on specific antimalarial agent used
Key clinical trials
- Improving Care Through Azithromycin Research for Infants in Africa (PHASE3)
- MULTIple Doses of IPTi Proposal: a Lifesaving High Yield Intervention
- Parasite Clearance and Protection from Infection (PCPI) in Cameroon (PHASE3)
- Perennial Malaria Chemoprevention (PMC) in Cameroon
- Perennial Malaria Chemoprevention (PMC) in Côte D'Ivoire
- Kilimanjaro IPTi Drug Options Trial (PHASE2, PHASE3)
- Efficacy of Amodiaquine-artesunate in Children Aged 6-59 Months With Uncomplicated P. Falciparum Malaria (PHASE4)
- Intermittent Preventive Treatment (IPTi) for the Prevention of Malaria and Anaemia in PNG Infants (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IPTi CI brief — competitive landscape report
- IPTi updates RSS · CI watch RSS
- Swiss Tropical & Public Health Institute portfolio CI